07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

AVN-211: Phase IIb data

A double-blind, Russian Phase IIb trial in 80 schizophrenic patients in incomplete remission on stable antipsychotic therapy showed that once-daily oral AVN-211 missed the primary endpoint of improving PANSS total score from baseline to week...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AV4025: Phase Ib data

A double-blind, placebo-controlled, Russian Phase Ib trial in 15 treatment-naïve patients with HCV genotype 1b infection showed that once-daily 20 and 40 mg doses of oral AV-4025 for 3 days were well tolerated with no...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Clinical News

AVR560: Phase Ib started

AllaChem began a double-blind, placebo-controlled Phase Ib trial to evaluate once-daily 100 and 150 mg oral AVR560 for 14 days in treatment-naïve HCV patients. AllaChem LLC , Hallandale Beach, Fla.   Product: AVR560   Business:...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

ONC1-13B: Phase I started

AllaChem began an open-label, dose-escalation Phase I trial to evaluate once-daily 40, 80, 160, 240 and 320 mg ONC1-13B for up to 72 weeks in up to 40 patients. AllaChem LLC , Hallandale Beach, Fla....
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

AV4025: Phase Ib started

AllaChem began a double-blind, placebo-controlled, Russian Phase Ib trial to evaluate 20 or 40 mg oral AV4025 once daily for 3 days in about 20 treatment-naïve patients with HCV infection. AllaChem LLC , Hallandale Beach,...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

AV4025: Phase I data

AllaChem LLC , Hallandale Beach, Fla.   Product: AV4025   Business: Infectious   Molecular target: HCV NS5A protein   Description: HCV NS5A inhibitor   Indication: Treat chronic HCV infection   Endpoint: Safety and pharmacokinetics  ...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

Alla Chem preclinical data

In vitro and in vivo, ONC1-13B led to greater antitumor activity as calculated per unit of concentration in plasma and had a lower potential for drug-drug interactions vs. Xtandi enzalutamide (formerly MDV3100 ) and ARN-509...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Clinical News

AV4025: Phase I started

Alla Chem LLC , Hallandale Beach, Fla.   Product: AV4025   Business: Infectious   Molecular target: HCV NS5A protein   Description: HCV NS5A inhibitor   Indication: Treat chronic HCV infection   Endpoint: Safety and pharmacokinetics...